Olaparib Tablets Approved in Europe for Ovarian Cancer, Regardless of BRCA Status

May 8, 2018 – The European Commission has approved olaparib tablets as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy, regardless of BRCA status. A capsule formulation of olaparib was previously approved in the European Union for use in this setting; however, its use is limited to patients with BRCA … (leggi tutto)